Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Net Cash Flow (2020 - 2025)

Historic Net Cash Flow for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Q3 2025 value amounting to $16.1 million.

  • Tarsus Pharmaceuticals' Net Cash Flow rose 42908.9% to $16.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$60.9 million, marking a year-over-year decrease of 2073.05%. This contributed to the annual value of -$127.6 million for FY2024, which is 18322.04% down from last year.
  • Latest data reveals that Tarsus Pharmaceuticals reported Net Cash Flow of $16.1 million as of Q3 2025, which was up 42908.9% from -$79.1 million recorded in Q2 2025.
  • In the past 5 years, Tarsus Pharmaceuticals' Net Cash Flow registered a high of $119.9 million during Q3 2023, and its lowest value of -$97.8 million during Q4 2022.
  • Moreover, its 5-year median value for Net Cash Flow was -$4.9 million (2024), whereas its average is -$2.8 million.
  • Per our database at Business Quant, Tarsus Pharmaceuticals' Net Cash Flow surged by 84459.75% in 2021 and then crashed by 446979.71% in 2024.
  • Quarter analysis of 5 years shows Tarsus Pharmaceuticals' Net Cash Flow stood at -$12.5 million in 2021, then tumbled by 684.58% to -$97.8 million in 2022, then skyrocketed by 98.24% to -$1.7 million in 2023, then tumbled by 4469.8% to -$78.8 million in 2024, then surged by 120.39% to $16.1 million in 2025.
  • Its Net Cash Flow was $16.1 million in Q3 2025, compared to -$79.1 million in Q2 2025 and $81.0 million in Q1 2025.